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Abstract
Background: Myeloid-derived suppressor cells (MDSC) and M2 monocytes/macrophages are two types of
suppressive myeloid antigen presenting cells that have been shown to promote tumor progression and correlate
with poor prognosis in cancer patients. Tumor antigen specific monoclonal antibodies (mAb) have emerged as
important agents for cancer therapy. In addition to the direct inhibition of tumor growth, the Fc portions of the
therapeutic mAbs, such as the IgG1 portion of the anti-epidermal growth factor receptor (EGFR) mAb cetuximab,
might interact with the Fc-gamma receptors (FcγR) on myeloid cells and modulate their suppressive activity.
Methods: Patients with locally advanced head and neck squamous cell carcinoma (HNSCC) on the UPCI 08–013
NCT01218048 trial were treated with single-agent cetuximab before surgery. Blood were collected pre- and
post-cetuximab treatment to analyze frequency of monocytic MDSC (CD11b+CD14+HLA-DRlo/-), granulocytic MDSC
(LIN−CD11b+CD15+) and CD11b+CD14+HLA-DRhi monocytes by flow cytometry. Besides, CD11b+CD14+HLA-DRhi
monocytes were sorted for qPCR analysis of IL-10 and IL-12B transcripts. MDSC were generated in vitro with or
without coated hIgG1 and tested for suppressive activity in mixed leukocyte reaction (MLR). Naïve monocytes from
HNSCC patients co-cultured with tumor cell lines in the presence of cetuximab or hIgG1 were analyzed for M1/2
surface markers and cytokines.
Results: We observed significantly increased monocytic MDSC in non-responders and decreased granulocytic
MDSC in responders after cetuximab treatment. In addition, circulating CD11b+CD14+HLA-DRhi monocytes of
cetuximab responders displayed attenuated M2 polarization, with decreased CD163+ expression and IL-10
transcripts after cetuximab treatment. This beneficial effect appeared to be FcγR dependent, since CD16 ligation
reproduced the reversal of suppressive activity of MDSC in vitro. CD14+ naïve monocytes from the co-cultures of
tumor cells, cetuximab and HNSCC patient PBMC or purified monocytes were skewed to an M1-like phenotype, with
increased expression of HLA-DR, CD86 and production of IL-12 p70. Likewise, reduced M2 features (expression of
CD163 and production of IL-10) were found after crosslinking CD16 on the surface of monocytes to cetuximab-coated
tumor cells.
Conclusion: Our studies demonstrate a novel function of cetuximab in ameliorating suppressive phenotypes of FcγR
bearing myeloid cells in cancer patients, which is associated with better clinical outcome of cetuximab-treated patients.
Clinical trial registry: #NCT01218048. Registered 7 October 2010.
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Background
Despite recent advances in surgery, chemotherapy and
radiotherapy, the overall 5-year survival rate for head
and neck squamous cell carcinoma (HNSCC) remains at
about 50 %. Cetuximab, an anti-epidermal growth factor
receptor (EGFR) monoclonal antibody, has become an
important targeted therapy for multiple types of solid
tumors and has been FDA approved for treating locally
advanced and recurrent/metastatic HNSCC. However,
response rates are only 15–20 % [1, 2], and its mechan-
ism of action has not been determined [3, 4]. Besides
inhibition of EGFR tyrosine phosphorylation and the
subsequent downstream signaling, the human IgG1 Fc
portion of cetuximab can activate NK cell-mediated
antibody dependent cell-mediated cytotoxicity (ADCC)
in a Fc-gamma receptor (FcγR)-dependent manner [5],
triggering enhanced antigen presentation and resulting
in an adaptive tumor-specific immune response [6].
However, since FcγRs are also widely expressed on mye-
loid antigen presenting cells (APC) in addition to NK
cells, cetuximab is also likely to modulate their pheno-
type and function.
Myeloid APC with potent immunosuppressive activ-
ities, including myeloid-derived suppressor cells (MDSC)
and M2 macrophages (MΦ)/monocytes (Mo), are in-
duced by multiple tumor-derived soluble factors from
the tumor microenvironment, and are utilized by the
tumor cells to facilitate immune evasion and to promote
tumor progression [7–9]. Increased abundance of MDSC
and M2 MΦ/Mo is associated with poor clinical out-
come [10–12] and is a major obstacle to existing cancer
therapies [8, 13]. Therefore, they represent novel thera-
peutic targets for manipulating the host immune re-
sponse against tumor cells. MDSC is a heterogeneous
population of immature myeloid cells first identified in
tumor-bearing mice as CD11b+Gr-1+ and can be
subdivided into two major classes: granulocytic and
monocytic MDSC. Granulocytic MDSC inhibit T cell re-
sponses mainly through reactive oxygen species (ROS)
[14, 15], while monocytic MDSC suppresses T cell by
depleting L-arginine via arginase-I and iNOS [16, 17].
In HNSCC patients, LIN−CD11b+CD15+ cells have
been characterized as granulocytic MDSC [18], while
CD11b+CD14+HLA-DRlo/- cells have been identified as
monocytic MDSC with immunosuppressive functions
[19]. M1/M2 polarization plays an important role in
modulating anti-tumor immune responses. M1, the clas-
sically activated MΦ/Mo induced by IFN-γ and bacterial
products, display high antigen presentation efficiency due
to upregulation of MHCII (HLA-DR) and co-stimulatory
molecules (CD80 and CD86), express high levels of IL-12
and low IL-10, and thus activate Tc1/Th1 anti-tumor
responses. In contrast, M2, the alternatively activated
MΦ/Mo induced by anti-inflammatory cytokines, produce
high levels of IL-10 and low levels of IL-12, and thus
inhibit development of Th1 cells and CTL responses and
facilitate tumor progression [17]. Therefore, polarization
of MΦ/Mo towards an M1 phenotype is indispensable to
enhance efficacy of anti-tumor immunotherapy.
Since CD16 receptor binds to the Fc portion of cetuxi-
mab and its intracellular immunoreceptor tyrosine-based
activation motif (ITAM) has been suggested to induce DC
maturation [20], we hypothesized that cetuximab can
skew these myeloid cells away from immunosuppressive
capacity of MDSC and M2 cells. In this study, we investi-
gated the effects of cetuximab on the well-reported abun-
dance of granulocytic and monocytic MDSC as well as the
M1/M2 polarization of monocytes in the peripheral circu-
lation in HNSCC patients, taking advantage of a phase II
trial of neoadjuvant cetuximab. In addition, we also uti-
lized in vitro generated MDSC in the presence or absence
of CD16 ligation in a suppression assay and co-culture of
tumor cells and PBMC or purified monocytes from
HNSCC patients with or without cetuximab, to further in-
vestigate the mechanism of cetuximab mediated MDSC
activity.
Results
Circulating monocytic MDSC increase in cetuximab
non-responding patients
Since monocytic myeloid-derived suppressor cells (MDSC)
have been shown to be enriched in the peripheral blood of
cancer patients, we investigated the population of circulat-
ing monocytic MDSC, the other subset of MDSC enriched
in HNSCC patients, characterized as CD14+HLA-DRlo/-,
in HNSCC patients on the UPCI 08–013 trial, a cetuximab
single agent trial in which the patients received weekly
doses of cetuximab for 3 to 4 weeks before surgery [19].
First, we examined the baseline frequency of circulating
CD14+HLA-DRlo/- in the CD11b+ compartment in the co-
hort of patients on the 08–013 trial of neoadjuvant cetuxi-
mab, as compared with healthy donors by flow cytometry
(gating strategy shown in Additional file 1: Figure S1A). As
expected, stage III/IV HNSCC patients showed sig-
nificantly higher CD14+HLA-DRlo/- cells in circulating
CD11b+ cells at baseline compared with healthy donors
(Fig. 1a). We then tested whether cetuximab treatment
altered the level of circulating monocytic MDSC in the
HNSCC patients.
Interestingly, a significant increase of monocytic MDSC
in CD11b+ cells (p = 0.01) and in whole peripheral blood
mononuclear cells (PBMC) (p = 0.01) was observed in
non-responder patients after cetuximab treatment. Sur-
prisingly, the baseline level of CD14+HLA-DRlo/- cells
within CD11b+ PBMC was higher in responders than in
non-responders (p = 0.02). However, the cetuximab
clinical responders did not show upregulation of cir-
culating monocytic MDSC. On the contrary, 7 of the 10
Li et al. Journal for ImmunoTherapy of Cancer  (2015) 3:54 Page 2 of 16
AB
C
Fig. 1 (See legend on next page.)
Li et al. Journal for ImmunoTherapy of Cancer  (2015) 3:54 Page 3 of 16
responders had decreased levels of monoctyic MDSC in
the peripheral circulation post-cetuximab, but this finding
did not reach statistical significance (Fig. 1b and c). The
baseline levels of CD16 expression on circulating mono-
cytic MDSC are similar between responders and non-
responders (Additional file 1: Figure S2), indicating differ-
ent clinical responses to cetuximab treatment are not due
to different baseline level of CD16. Our data indicates that
cetuximab can overcome the enrichment of circulating
monocytic MDSC in patients with advanced HNSCC,
with the possibility of decreasing these cells in a subset of
clinical responders.
Decreased circulating granulocytic MDSC in HNSCC
patients after cetuximab treatment
Having demonstrated the changes of monocytic MDSC
in the patients of the 08–013 trial, we next studied the
abundance of circulating granulocytic MDSC, the other
subset of MDSC, in our cohort of HNSCC patients.
First, we compared the frequency of granulocytic MDSC
(LIN−CD11b+CD15+) in the circulation of healthy donors
and HNSCC patients prior to cetuximab treatment (gating
strategies shown in Additional file 1: Figure S1A). Consist-
ent with previous report [18], we observed much higher
levels of circulating LIN−CD11b+CD15+ in HNSCC pa-
tients than in healthy donors (Fig. 2a, p < 0.01). Next, we
examined the frequency of circulating granulocytic MDSC
in this cohort of HNSCC patients pre- and post-cetuximab
treatment. Interestingly, the overall percentage of granulo-
cytic MDSC significantly decreased in the circulation of the
24 patients tested (p = 0.008). However, a significant and
consistent decrease in the abundance of circulating
granulocytic MDSC was observed only in the cetuximab
responders (n = 8, p = 0.008) as compared to cetuximab-
resistant patients (n = 16) (Fig. 2b and c). Our findings
suggest that cetuximab treatment might modulate the
development of granulocytic MDSC in HNSCC patients.
Decreased CD163+ cells and IL-10 transcripts in
circulating CD11b+CD14+HLA-DRhi monocytes in
cetuximab-treated responders
Next, we investigated another major subpopulation of
CD14+ circulating monocytes, specifically CD14+HLA-
DRhi cells that are likely to be precursors of tissue mac-
rophages, to analyze whether cetuximab treatment alters
their M1/M2 phenotypic skewing in HNSCC patients on
the cetuximab neoadjuvant trial. First, we analyzed
expression of CD163, a scavenger receptor usually used
as an M2 surface marker and up-regulated by anti-
inflammatory cytokines such as IL-10 and IL-6 [21], on
circulating CD11b+CD14+HLA-DRhi monocytes. Al-
though there was no significant difference in frequency
of CD163+ cells in CD11b+CD14+HLA-DRhi mono-
cytes in the circulation of HNSCC patients tested
overall (n = 29) pre- and post-cetuximab treatment,
we observed a significant decrease in percentage of
CD163+ cells in circulating CD11b+CD14+HLA-DRhi
monocytes in the cetuximab clinical responders (n = 9,
p = 0.049) (Fig. 3a and b). These findings suggest that
cetuximab treatment might lessen M2 skewing of
circulating monocytes or potentially induce a more benefi-
cial anti-inflammatory environment in the HNSCC pa-
tients’ tumors.
In order to investigate the M1/M2 skewing of circulating
CD11b+CD14+HLA-DRhi monocytes in the cetuximab-
treated patients more definitively, we sorted the
CD11b+CD14+HLA-DRhi from the patient PBMC pre-
and post-cetuximab treatment by FACS sorting and
purified the RNA for real time qPCR analysis of IL-12B
(produced by M1 or mature dendritic cells) and IL-10
(mainly produced by M2) transcripts. While IL-12 tran-
scripts in circulating CD11b+CD14+HLA-DRhi monocytes
were too low to be determined, expression of IL-10 tran-
scripts was down-regulated in CD11b+CD14+HLA-DRhi
monocytes from HNSCC patient PBMC (n = 14, p = 0.02)
after cetuximab treatment. Moreover, circulating
CD11b+CD14+HLA-DRhi monocytes from cetuximab
responders showed consistent and significant decreased IL-
10 transcripts post-cetuximab treatment (n = 6, p = 0.03),
while some of the cetuximab non-responders (n = 8)
manifested increased IL-10 transcripts in circulating
CD11b+CD14+HLA-DRhi monocytes (Fig. 3c). These find-
ings indicate that the CD11b+CD14+HLA-DRhi mono-
cytes in the peripheral circulation of cetuximab-treated
patients displayed less M2 skewing, including with de-
creased expression of IL-10 transcripts.
(See figure on previous page.)
Fig. 1 Circulating monocytic MDSC (CD11b+CD14+HLA-DRlo/-) increased after cetuximab treatment in non-responders after cetuximab neoadjuvant
therapy. Levels of monocytic MDSC (CD11b+CD14+HLA-DRlo/-) in the peripheral blood of healthy donors versus HNSCC patients and HNSCC patients
pre- and post-cetuximab treatment were analyzed by flow cytometry. a Representative figures showing frequency of CD14+HLA-DRlo/- cells in CD11b+
mononuclear cells in peripheral blood from healthy donors and HNSCC patients. The mean LIN−CD11b+ cells from healthy donors and HNSCC patients
were not statistically different. b Representative figures showing percentage of CD14+HLA-DRlo/- cells in circulating CD11b+ cells from responders and
non-responders of UPCI 08–013 trial before and after cetuximab treatment. c Summary data of frequency of CD14+HLA-DRlo/- cells in CD11b+ PBMC
or in total live PBMC pre- and post-cetuximab treatment in the total 40 HNSCC patients (left panel) and in responders (n = 10) and non-responders
(n = 19) of UPCI 08–013 trial (right panel). Statistical significance was determined by Wilcoxon matched-pairs signed rank tests for the same patients
pre- and post-cetuximab treatment and Mann Whitney test for baseline levels in responders versus non-responders. *p < 0.05
Li et al. Journal for ImmunoTherapy of Cancer  (2015) 3:54 Page 4 of 16
AB
C
Fig. 2 Granulocytic MDSC (LIN−CD11b+CD15+) in the peripheral blood of HNSCC patients decreased after cetuximab treatment. Levels of granulocytic
MDSC (LIN−CD11b+CD15+) in the peripheral blood of healthy donors versus HNSCC patients and patients pre- and post-cetuximab treatment were
analyzed by flow cytometry. a Representative figures showing frequency of CD15+ cells in LIN−CD11b+ mononuclear cells in peripheral blood from
healthy donors and HNSCC patients. b Representative figures showing percentage of CD15+ cells in circulating LIN−CD11b+ cells in HNSCC patients
before and after cetuximab treatment. c Summary data of frequency of LIN−CD11b+CD15+ cells in live PBMC pre- and post-cetuximab treatment in
the total 24 HNSCC patients (left panel, **p < 0.01) and in responders (n = 8, **p < 0.01) and non-responders (n = 16) of UPCI 08–013 trial (right panel).
Statistical significance was determined by Wilcoxon matched-pairs signed rank tests. **p < 0.01. p > 0.05 was considered to be not significant (n.s.)
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FcγR ligation can reverse the suppressive effects of
IL-6 + GM-CSF-induced MDSC on T cell proliferation
Since FcγR are widely expressed on myeloid cells, and the
Fc portion of cetuximab, human IgG1 (hIgG1), can bind
to FcγR such as FcγRIII (CD16) and trigger the down-
stream signaling, we hypothesized that cetuximab may
directly act on the FcγR on the myeloid cells to ameliorate
their suppressive phenotypes in cancer patients. In order
to test this possibility, we took advantage of an established
in vitro induction procedure for MDSC from peripheral
blood of healthy donors to test whether ligating the FcγR
to hIgG1 Fc domains changes the phenotypes and sup-
pressive functions of the in vitro induced MDSC. We
coated hIgG1 (10 μg/mL) to polystyrene flasks and plated
the PBMC isolated from healthy donors (n = 3) in the
hIgG1-coated flasks or uncoated flasks, in the presence or
absence of 10 ng/mL IL-6 and GM-CSF for 7 days. Surface
markers were analyzed by flow cytometry and CD33+
myeloid cells were isolated and cultured with the CFSE-
labeled autologous T cells to test suppressive activity.
Expression of HLA-DR was downregulated in the
presence of IL-6 and GM-CSF, which is consistent with
the expectation that MDSC have deficient HLA-DR ex-
pression, while ligation of FcγR by polyvalent hIgG1 in-
creased HLA-DR expression in these MDSC inducing
conditions (Fig. 4a). Furthermore, while IL-6 and GM-
CSF-induced MDSC strongly suppressed proliferation of
autologous T cells (Fig. 4b, p = 0.03), the presence of
hIgG1 coated surfaces during the in vitro induction ame-
liorated the suppressive effects of cytokine-induced MDSC
on T cells (Fig. 4b, p = 0.02). Notably, we observed a con-
comitant down-regulation of CD16, but not CD32a or
CD32b on the surface of CD33+ cells cultured in the
hIgG1-coated flask (Fig. 4c), indicating hIgG1 mainly in-
teracts with CD16 but not CD32a/b on the myeloid cells.
Taken together, our data indicates that cetuximab can
skew circulating myeloid cells away from MDSC-like sup-
pressive phenotypes toward an FcγR-dependent manner.
Cetuximab skews monocytes co-cultured with tumor cells
to an M1 instead of M2 phenotype
Having demonstrated that CD11b+CD14+HLA-DRhi
monocytes in the peripheral circulation of cetuximab
responders showed attenuated M2 skewing with de-
creased CD163+ cells and IL-10 transcripts after cetuxi-
mab treatment, we next investigated whether cetuximab
alters M1/M2 skewing of naïve monocytes in vitro. Total
PBMC or purified monocytes from HNSCC patients
with new active diseases (n = 9) were co-cultured with
PCI15B or JHU029 (HNSCC cell lines with high EGFR ex-
pression) for 3 days with 10 μg/mL cetuximab or hIgG1
(isotype control), before analysis of surface markers on
CD14+ monocytes by flow cytometry. As expected, expres-
sion of HLA-DR and CD86, which are well known as
markers of M1 macrophages, were up-regulated on CD14+
monocytes within PBMC co-cultured with tumor cells in
the presence of cetuximab (p = 0.004). In addition, upregu-
lation of PD-L1, which correlates with the activation status
of monocytes [22], was more pronounced on monocytes
incubated with cetuximab versus control mAb (p = 0.004).
Moreover, naïve monocytes co-cultured with tumor cells
showed decreased expression of CD163, the scavenger re-
ceptor expressed on M2 suppressive microphages, only in
the presence of cetuximab (p = 0.004, Fig. 5a and b). Simi-
lar changes of surface markers on CD14+ monocytes were
also observed in the co-cultures of tumor cells and purified
monocytes with cetuximab in the absence of NK cells
(Fig. 5c and d), indicating M1/M2 skewing of naïve mono-
cytes altered by cetuximab is NK-independent.
Cetuximab down-regulates surface expression of CD16 on
monocytes only in the presence of EGFR-expressing
tumor cells
Activation of NK cells by cross-linking of CD16 with
cetuximab-coated tumor cells resulting in loss of surface
CD16 due to internalization [23, 24]. Thus, we investigated
whether monocytes can be activated by cetuximab-coated
tumor cells in a similar CD16-dependent manner. Surface
expression of CD16 was analyzed on CD14+ monocytes
from PBMC and purified monocytes from HNSCC pa-
tients cultured with or without PCI15B or JHU029 in the
presence of 10 μg/mL cetuximab or hIgG1. CD14+ mono-
cytes showed significantly decreased CD16 surface expres-
sion when cultured with cetuximab-coated tumor cells
(Fig. 5e, p = 0.004), concomitant with upregulation of M1
and down-regulation of M2 markers (Fig. 5a-d). In
(See figure on previous page.)
Fig. 3 Cetuximab responders showed decreased CD163+ cells and IL-10 transcripts in circulating CD11b+CD14+HLA-DRhi monocytes after cetuximab
treatment. a Representative figures showing percentage of CD68+CD163+ cells in circulating CD11b+CD14+HLA-DRhi cells from responders
and non-responders during, pre- and post-neoadjuvant cetuximab treatment. b Summary data of frequency of CD163+ cells in CD11b+
CD14+HLA-DRhi monocytes in the peripheral circulation pre- and post-cetuximab treatment in the total 29 HNSCC patients (left panel) and in responders
(n = 10, *p < 0.05) and non-responders (n = 19) of UPCI 08–013 trial. Circulating CD11b+CD14+HLA-DRhi monocytes were sorted from PBMC of 14
cetuximab treated patients and RNA was isolated for real time quantitative PCR analysis of IL-10 transcripts. c Summary data showing relative IL-10
expression in circulating CD11b+CD14+HLA-DRhi monocytes pre- and post-cetuximab treatment in the total 14 HNSCC patients tested (left panel,
*p < 0.05) and in responders (n = 6, *p < 0.05) and non-responders (n = 8) in the neoadjuvant cetuximab trial (right panel). The quantity of each
cDNA sample was normalized by GUSB. All of the experiments were performed in triplicate. Statistical significance was determined by Wilcoxon
matched-pair signed rank tests. *p < 0.05. p > 0.05 was considered to be not significant (n.s.)
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contrast, PBMC or purified monocytes treated with cetuxi-
mab in the absence of EGFR-expression tumor cells did
not show altered CD16 surface expression (Fig. 5f) and no
difference in M1 and M2 markers were observed (data not
shown). These findings indicate that cetuximab-coated
tumor cells polarize naïve monocytes to M1 cells by direct
crosslinking of CD16 on the monocytes by the hIgG1 Fc
portion of cetuximab.
Cetuximab down-regulates surface expression of CD16 on
monocytes only in the presence of EGFR-expressing
tumor cells
Since production of IL-12 p70 and IL-10 are key func-
tional mediators of M1 and M2 cells [25], respectively,
we also examined IL-12 p70 and IL-10 cytokines in the
supernatants of co-culture between tumor cells and
PBMC or purified monocytes, incubated with or without
cetuximab. PBMC or purified monocytes from HNSCC
patients co-cultured with tumor cells had increased pro-
duction of IL-12 p70 (Fig. 6a, p = 0.02) and decreased
production of IL-10 (Fig. 6b, p = 0.02) in the presence of
cetuximab. Taken together, our data suggest that cetuxi-
mab can skew naïve monocytes toward an M1-polarized
phenotype when co-cultured with EGFR+ tumor cells,
including upregulation of M1 surface markers and cyto-
kines and reduced M2 characteristics.
Discussion
Pander et al. previously suggested that M2 macrophages
are activated in the tumor microenvironment by
addition of cetuximab to bevacizumab and chemother-
apy in a randomized phase III clinical trial of metastatic
colorectal cancer (CRC) patients [26], which seems to
contradict with our current findings. However, the actual
correlation of M2 macrophages in the tumor micro-
environment with cetuximab treatment was not shown.
In addition, their study was a combinational therapy of
cetuximab, bevacizumab and chemotherapy, instead of a
single agent therapy of cetuximab as we present here.
Therefore, we cannot rule out the possibility that their
in vivo observations are a complex result of multiple
therapeutic interventions, rather than cetuximab alone.
Instead, in our study, we took advantage of a prospective
cetuximab single agent trial (UPCI 08–013) to explore
the effects of cetuximab on myeloid cells in vivo and
demonstrated that cetuximab treatment attenuated M2
phenotypes of circulating CD11b+CD14+HLA-DRhi mo-
nocytes in 08–013 responders with decreased expression
of CD163 and IL-10 transcripts (Fig. 3). Pander et al.
used in vitro differentiated M2 macrophages to co-
culture with cetuximab-coated tumor cells instead of
naïve monocytes as we did in this study. The upregula-
tion of PD-L1 and IL-10 expression on M2 macrophages
might be due to general activation of monocytes instead
of specific skewing towards M2 by cetuximab. In our in
vitro co-culture studies, we observed upregulation of
PD-L1 but decreased production of IL-10 and increased
production of IL-12 p70 in the presence of cetuximab-
coated tumor cells (Figs. 5 and 6), indicating cetuximab
coated on tumor cells skews naïve monocytes towards
an M1 but not M2 polarization, and PD-L1 is not a
necessary marker for M2 MΦ/Mo. In addition, we used
a higher concentration of cetuximab in our in vitro
studies, (10 μg/mL versus their 1 μg/mL) and studied
different disease contexts (HNSCC versus CRC), which
might also contribute to the different observations.
Taken together, we conclude that cetuximab could
ameliorate suppressive phenotypes of antigen presenting
myeloid cells, skewing them away from MDSC and M2
MΦ/Mo, which is firmly supported by both in vivo and
in vitro findings.
Due to small sample size (a cohort of 29 patients) and
variable preliminary nature of the patients, some of our
analyses only showed a trend of increase or decrease,
but did not turn out to be statistically significant. Thus,
we were not able to segregate the patients into different
groups according to certain characteristics. Therefore,
those findings might not be convincing enough to be
applied to all the patients and require validation in inde-
pendent cohorts. However, we still observed some con-
sistent changes in responders or non-responders after
cetuximab treatment, such as decreased granulocytic
MDSC in the PBMC of responders (decreased in every
responder patients after cetuximab treatment). These
findings can be used as biomarkers for prognosis. More-
over, since this trial is a cetuximab single agent trial, we
(See figure on previous page.)
Fig. 4 Ligation to flask-coated hIgG1 could reverse the suppressive effects of IL-6 + GM-CSF-induced MDSC on T cell proliferation. Total PBMC
were isolated from peripheral blood of 3 healthy donors, plated in regular flasks or hIgG1-coated flasks (5 × 105/mL) supplied with or without
10 ng/mL IL-6 and 10 ng/mL GM-CSF and cultured for 7 days. Then cells were harvested and surface markers were analyzed by flow cytometry.
a Representative figure showing expression levels of HLA-DR on CD33+ myeloid cells from the indicated conditions. CD33+ cells were also
isolated by FACS sorting and co-cultured with CFSE-labeled autologous T cells (105 cells/well) at a 1:2 ratio. T cell stimulation was provided by
anti-CD3/CD28 magnetic beads (bead: cell = 1:1). CFSE dilution was analyzed by flow cytometry for T cell proliferation after 3 days. b Summary
data of proliferation of T cells co-cultured with CD33+ cells from the above cultures is shown. Proliferation of T cells in each condition was
normalized to the matched T cell alone condition (100 %). The graph presents the mean ± SEM from 3 different healthy donors. Statistical significance
was determined by one-way ANOVA followed by Tukey multiple comparison test. *p < 0.05. c Summary data showing expression level of surface
CD16, CD32a and CD32b on CD33+ myeloid cells from the indicated conditions
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can infer much more clear indications about the im-
munologic effects of cetuximab alone on the patients,
without complicating effects of chemotherapy and/or
radiotherapy.
Activated NK cells are able to enhance DC maturation
and mature DC can secrete IL-12 to elongate the
duration of NK activation, as a reciprocal crosstalk mech-
anism of NK: DC crosstalk [6, 27]. Therefore, a question
is raised whether cetuximab-mediated attenuation of
suppressive phenotypes of myeloid cells is dependent on
NK cells. Notably, the purified CD14+ monocytes (purity:
up to 97 %) could be skewed to M1 phenotypes with in-
creased expression of M1 surface markers and production
of IL-12 p70 even in the absence of NK cells. In addition,
down-regulation of CD16, but not CD32a/b, was observed
on in vitro induced MDSC with FcγR: hIgG1 ligation
(Fig. 4c) and monocytes co-cultured with cetuximab-
coated tumor cells (Fig. 5e), indicating CD16 is
A
B
Fig. 6 IL-12 p70 was increased and IL-10 was decreased in the supernatants of the co-cultures of tumor cells and PBMC or purified monocytes in the
presence of cetuximab. Supernatants of the PBMC/monocyte + tumor co-culture described above were collected and subjected to measurement of
IL-12 p70 and IL-10 by ELISA. Summary data of IL-12 p70 (a) and IL-10 (b) in the supernatants of cultures of PCI15B+ PBMC, JHU029+ PBMC, PCI15B+
purified monocytes and JHU029+ purified monocytes with 10 μg/mL hIgG1 or cetuximab is shown. The graphs present the experiments from 8
different HNSCC patients with new active diseases. Statistical significance was determined by Wilcoxon matched-pairs signed rank tests. *p < 0.05
(See figure on previous page.)
Fig. 5 Expression of HLA-DR, CD86 and PD-L1 were increased, while expression of CD163 was decreased on CD14+ monocytes,concomitant with
downregulation of CD16, in the co-cultures of tumor cells and PBMC or purified monocytes in the presence of cetuximab. Total PBMC or purified
monocytes from HNSCC patients with new active diseases (n = 9) were co-cultured with PCI15B or JHU029 for 3 days with 10 μg/mL hIgG1 or
cetuximab before analysis of surface markers on CD14+ monocytes by flow cytometry. Summary graphs showing fold changes (MFI normalized to
each isotype) of HLA-DR, CD86, PD-L1 and CD163 on CD14+ monocytes from PCI15B+ PBMC (a), JHU029+ PBMC (b), PCI15B+ purified monocytes
(c) and JHU029+ purified monocytes (d) co-cultures supplied with 10 μg/mL hIgG1 or cetuximab. Surface expression of CD16 of gated CD14+
monocytes from the co-cultures of tumor cells and PBMC/monocytes indicated above or cultures of PBMC/monocytes alone without tumor
cells was analyzed by flow cytometry. Summary graphs of fold change of CD16 on CD14+ monocytes from the co-cultures of tumor cells and
PBMC/monocytes (e) and cultures of PBMC/monocytes in the absence of EGFR+ tumor cells (f) are shown. The graphs present the mean ± SEM
from advanced disease HNSCC patients (n = 9). Statistical significance was determined by Wilcoxon matched-pair signed rank tests. **p < 0.01
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internalized after interacting with the hIgG1 Fc portion of
cetuximab and hIgG1 mainly interact with CD16 instead
of CD32a or CD32b. In conclusion, our data suggest
skewing of myeloid cells away from suppressive phe-
notypes by cetuximab is NK-independent. However,
cetuximab-activated NK cells would be expected to en-
hance the M1 polarization of naïve monocytes with fur-
ther enhanced up-regulation of HLA-DR and CD86 as
well as amount of secreted IL-12 p70 (Figs. 5 and 6).
According to our findings, increased frequency of cir-
culating monocytic MDSC is correlated to poor clinical
response, though we also observed higher frequency of
circulating monocytic MDSC in responders at baseline
level (Fig. 2). We also noted that a higher frequency of
Treg have been observed at baseline in cetuximab clin-
ical responders compared to non-responders [28]. It is
possible that responders have stronger initial induced
anti-tumor immune responses and concomitantly more
immunosuppressive cells (MDSC and Treg) at baseline
(before cetuximab treatment). Besides, decreased M2
polarization of CD11b+CD14+HLA-DRhi monocytes in
the peripheral circulation was also correlated with better
clinical outcome (Fig. 3), which is consistent with previ-
ous reports that increased abundance of MDSC and M2
MΦ/Mo correlated with poor prognosis in cancer pa-
tients [10, 29]. In conclusion, cetuximab enhances anti-
tumor immune responses in HNSCC patients not only
by activating NK-mediated ADCC, but also by amelior-
ating suppressive phenotypes of myeloid antigen pre-
senting cells, which is associated with better outcome in
treated HNSCC patients. Since circulating monocytic
MDSC were more abundant in patients did not respond
to cetuximab treatment, MDSC depletion or inhibition
reagents should be considered to use in combination
with cetuximab to improve the efficacy of cetuximab
therapy.
Conclusion
In this study, we provide a novel insight for how cetuximab
modulates the immune system in HNSCC patients by
ameliorating the MDSC and M2 immunosuppression, and
its clinical significance, based on our in vivo and in vitro
observations. First, we demonstrate increased frequency of
circulating monocytic MDSC in non-responders and re-
duced abundance of circulating granulocytic MDSC in
cetuximab-treated HNSCC patients compared to pretreat-
ment levels. Second, CD11b+CD14+HLA-DRhi monocytes
in the peripheral blood of cetuximab responders showed
less M2 polarization with decreased expression of CD163
and IL-10 transcripts. Third, our in vitro FcγR: hIgG1
ligation was able to reverse the immunosuppression of the
IL-6 and GM-CSF induced MDSC, indicating the effect of
cetuximab on the development of MDSC is FcγR-
dependent. Fourth, cetuximab skewed naïve monocytes
towards M1 phenotypes, with upregulation of surface
expression of HLA-DR and CD86 and production of IL-12
p70 as well as decreased M2 characteristics (expression of
surface CD163 and IL-10 cytokine), concomitant with
down-regulation of surface CD16 expression. These data
suggest an important role for therapeutic tumor-targeted
mAb in promoting immunostimulatory phenotypes of
APC in treated patients.
Methods
Patients and specimens
All patients were seen in the Department of Otolaryngology
at the University of Pittsburgh Medical Center, and speci-
mens from patients were obtained by informed consent
under the IRB approved UPCI protocol 99–069. This
study was approved by University of Pittsburgh IRB and it
was a single site trial. PBMC were obtained from HNC pa-
tients receiving neoadjuvant cetuximab on a prospective
phase II clinical trial (UPCI #08-013, NCT 01218048).
Tumors were biopsied immediately before, and again after
4 weeks, of cetuximab therapy. Clinical response was ana-
lyzed by comparing paired CT scans pre/post cetuximab,
and quantifying tumor measurement by a dedicated head
and neck radiologist blinded to patient status. Anatomic
tumor measurements were recorded in two dimensions
and the cohort segregated into clinical “responders,” who
demonstrated reduction in tumor volume, or “non-re-
sponders,” whose tumors grew during this therapy. This is
a validated method to correlate clinical response, and this
was the primary, pre-specified endpoint in the clinical trial
(UPCI #08-013), funded and peer-reviewed by NIH R01
DE019727. Furthermore, the approach has been published
[28, 30, 31]. Traditional RECIST criteria are not appro-
priate for short “window of opportunity” (neoadjuvant)
biomarker therapeutic trials seeking to identify earlier
response biomarkers associated with objective clinical
response. Clinico-pathologic features of the responders
and non-responders are described in Table 1.
Peripheral venous blood samples were collected from
a cohort of 9 stage III/IV HNSCC patients with newly
diagnosed, untreated disease for in vitro studies of tumor
cell and PBMC/monocyte studies.
Table 1 Summary of clinicopathological features of the
responders and non-responders on the UPCI 08-013 trial
No. of
patients
Gender Mean
age
Tumor
site
HPV
status
Responders 10 Male: 6 60 OC: 8 HPV+: 1
Female: 4 OP: 2 HPV-: 9
Non-responders 19 Male: 14 59 OC: 8 HPV+: 9
Female: 5 OP: 9 HPV-: 10
L: 2
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Collection of peripheral blood mononuclear cells (PBMC)
Venous blood from HNSCC patients was drawn into
heparinized tubes and centrifuged on Ficoll-Hypaque
gradients (GE Healthcare Life Sciences, Piscataway, NJ).
PBMC were recovered, washed in RPMI-1640 medium
(Sigma, St. Louis, MO), and either used immediately for
experiments or resuspended in freezing media contain-
ing 10 % DMSO and 90 % FBS, transferred to Mr. Frosty
containers (Thermo Scientific, Waltham, MA), and
stored at −80 °C. Frozen PBMC were thawed in 37 °C
waterbath and transferred to 15 mL conical tube. Pre-
warmed RPMI-1640 medium containing 10 % FBS was
added dropwise to the thawed cells. After centrifuging
the cells to remove the freezing media, the cells can be
used for flow cytometry or in vitro experiment.
Antibodies and flow cytometry
The following anti-human antibodies were used for
staining: CD68-FITC, CD14-PercP-Cy5.5, HLA-DR-APC,
CD15-PE-Cy7, CD11b-PercP-Cy5.5, CD163-BV421, CD14-
APC, HLA-DR-PE, CD33-BV421 and PD-L1-BV421 pur-
chased from Biolegend (San Diego, CA), CD11b-PE, CD3-
Alexa Fluor 700, CD19-Alexa Fluor 700, CD19-Alexa Fluor
700, CD163-Alexa Fluor 647, CD16-PE-Cy7, CD3-PE,
CD19-PE and CD56-PE purchased from BD Biosciences
(San Jose, CA), CD14-PE-TR and CD16 PE-TR purchased
from Life Technologies (Carlsbad, CA) and CD86-FITC
purchased from R&D systems (Minneapolis, MN). CD32-
a-FITC Ab was purchased from Stemcell technologies,
(Vancouver, Canada). CD-32-B (F-4) was purchased from
Santa Cruz Biotechnology, Santa Cruz, CA, and secondary
Ab anti-mouse F(ab’)2 was purchased from Thermo fisher
scientific (MA, USA).
Intracellular staining of CD68 was performed as
follows: PBMC were stained with surface marker
antibodies, fixed with fixation/permeabilization buffer
(eBioscience), washed, and stained for intracellular anti-
gens in 1X permeabilization buffer. Cells were analyzed
on an LSR Fortessa (BD) flow cytometer, and data ana-
lyzed using Flow Jo (Treestar, Ashland, OR). Dead cells
were excluded based on viability dye staining (Zombie
Aqua Fixable Viability Dye, Biolegend).
Sorting of CD11b+CD14+HLA-DRhi circulating monocytes
from patients and quantitative real-time PCR
PBMC from HNSCC patients was obtained pre- and
post-cetuximab treatment (on the UPCI 08–013 trial
Table 2) were thawed and stained with CD11b-PercP-
Cy5.5, CD14-APC and HLA-DR-PE antibodies. CD11b
+ CD14 + HLA-DRhicells were sorted using Beckman
Coulter MoFlo Astrios (Brea, CA). Sorted cells were
then lysed in RLT lysis buffer and subjected to RNA
purification using RNeasy Mini Kit (Qiagen, Valencia,
CA) and Purelink DNase Set (Invitrogen, Grand Island,
NY). The concentration and purity of RNA was deter-
mined by measuring absorbance at 260 and 280 nm.
RNA was used for first strand cDNA synthesis using
random hexamers and MultiScribe reverse transcriptase
(Applied Biosystems, Foster City, CA) according to man-
ufacturer’s instructions. PCR probes for IL-12B
(Hs01011518_m1), IL-10 (Hs00961622_m1) and GUSB
(Hs99999908_m1) were purchased from Applied Biosys-
tem for TaqMan® Gene Expression Assay. Real-time
PCR cycling was performed using StepOne™ Real-
Time PCR Systems (Applied Biosystems, Carlsbad,
CA). GUSB was amplified as an internal control. All of
the experiments were performed in triplicates. Relative ex-
pression of the target genes to endogenous control gene
(GUSB) was calculated using the ΔCT method: relative ex-
pression = 2−ΔCT, where ΔCT = CT (target gene) − CT
(GUSB).
hIgG1 ligation assay
10 μg/mL human IgG1 (Southern Biotech, Birmingham,
AL) dissolved in 1X ELISA coating buffer (Biolegend,
San Diego, CA) was added to T-75 flasks. Then the
flasks were incubated for 2 h at 37 °C or overnight at
4 °C. Coated flasks were washed with sterile PBS 3
times before use.
In vitro monocyte induction of MDSC and MDSC
suppression assay
PBMC isolated from healthy donors (n = 3) were
plated in the hIgG1-coated flasks or uncoated flasks
at 5X105 cells/mL in complete medium for 7 days, sup-
plied with or without 10 ng/mL IL-6 and GM-CSF (R&D
systems, Minneapolis, MN). Medium and cytokines were
refreshed every 2–3 days. After 7 days, all cells were har-
vested from the cultures. Adherent cells were removed
using trypsin. Some of the harvested cells were subjected
to analysis of surface markers by flow cytometry. The
other cells were stained with CD33-BV421, CD3-PE,
CD19-PE and CD56-PE and CD3−CD19−CD56−CD33+
cells from each culture were isolated using FACS sorting
(Beckman Coulter MoFlo Astrios, Brea, CA).
Fresh T cells were isolated from PBMC of autologous
donors by Human T cell Enrichmen Kit (Stemcell
Technologies, Vancouver, Canada) and were CFSE-
labeled (2 μM, Life Technologies, Carlsbad, CA) and
seeded in 96-well plates at 1X105 cells per well. CD33+
cells isolated from the cultures indicated above were
added to these wells at a 1:2 ratio of CD33+ cells: T
cells. T cell stimulation was provided by anti-CD3/
CD28 stimulation beads (Invitrogen, Carlsbad, CA) at a
1:1 ratio of T cells: beads. Suppression assay wells were
analyzed by flow cytometry for T cell proliferation after
3 days.
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Tumor cell: PBMC/purified monocyte co-culture studies
PBMC were isolated from 9 HNSCC patients with newly
diagnosed diseases. CD14+ monocytes were purified
from PBMC using EasySep human CD14 positive selec-
tion kit (Stemcell Technologies, Vancouver, Canada).
PCI15B or JHU029 were seeded in 96-well plates at
1X104 cells per well. PBMC were added to these cells at
a ratio of 1:10 (tumor cells: PBMC) and purified mono-
cytes were added at a ratio of 1:5 (tumor cells: mono-
cytes) with 10 μg/mL cetuximab or hIgG1 (Southern
Biotech, Birmingham, AL). Cells were harvested for flow
cytometry analysis of surface markers and supernatants
were collected and stored in −80 °C after cultured for
3 days.
ELISA
IL-12 p70 and IL-10 in the supernatants of the co-
cultures indicated above were tested using Human IL-12
p70 ELISA Kits and Human IL-10 ELISA Kits (Thermo
Scientific, Rockford, IL), per manufacturer’s instructions.
Statistical analysis
Averages were calculated as means. Two-group com-
parison was performed using paired Wilcoxon signed
rank text in GraphPad Prism (GraphPad, La Jolla,
CA). Experimental data with more than 2 comparison
groups were analyzed using one-way ANOVA with
post hoc pairwise comparisons using Tukey’s multiple
Table 2 Clinicopathological features of the 29 HNSCC patients on the UPCI 08-013 trial
Patient Gender Age Tumor site T-stage, clinical N-stage, clinical M-stage, clinical T-stage, path N-stage, path M-stage, path HPV status
1 Male 31 OC T3 N0 M0 T2 N1 M0 -
2 Male 51 OC T4 N1 M0 T4A N0 M0 -
3 Male 48 OP T2 N2 M0 T3 N2B MX +
4 Female 68 OC T4A N1 M0 T4A N0 MX +
5 Male 62 OP T1 N1 M0 T1 N2A MX +
6 Male 69 OP T2 N2 M0 T3 N2B MX +
7 Female 75 OC T4 N0 M0 T4A N0 MX -
8 Male 65 OC T2 N2 M0 T1 N2A MX -
9 Male 49 OP T1 N2B M0 T2 N1 MX +
10 Female 40 OC T2 N2B M0 T2 N2B MX -
11 Female 58 OC T3 N2B M0 T2 N2B MX -
12 Female 83 OC T4A N0 M0 T4A N0 MX -
13 Male 55 L T3 N1 M0 T3 N1 MX -
14 Male 64 OC T1 N1 M0 T1 N1 MX -
15 Female 51 OP T4 N0 M0 T2 N0 MX -
16 Male 59 OP T2 N2B M0 T2 N2A MX +
17 Male 64 OP T2 N1 M0 T2 N2B MX +
18 Male 62 OC T2 N0 M0 TX N0 MX -
19 Male 54 OC T2 N2C M0 T2 N2C MX -
20 Male 62 OC T4 N1 M0 T2 N1 MX -
21 Male 93 OC T4A N0 M0 TX NX MX -
22 Male 58 OP T2 N1 M0 T3 N1 MX -
23 Female 47 OC T4A N1 M0 T4A N1 MX -
24 Male 59 OC T4A N0 M0 T4A N0 MX -
25 Male 64 OP T2 N1 M0 T1 N1 MX +
26 Male 43 OP T2 N2B M0 T2 N2B MX +
27 Female 74 L T4 N1 M0 T3 N2C MX -
28 Female 57 OC T4A N1 M0 T2 N1 MX -
29 Male 57 OP T3 N2B M0 T1 N0 MX +
Abbreviations: OC oral cavity, OP oropharynx, L larynx
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comparison test. P-values < 0.05 were considered to
be significant. *p < 0.05, **p < 0.01.
Additional file
Additional file 1: Figure S1. Gating strategies of monocytic MDSC and
granulocytic MDSC in the peripheral blood. Gating strategies of flow
cytometry analysis of monocytic MDSC (CD11b+CD14+HLA-DRlo/-) and
granulocytic MDSC (Lin−CD11b+CD15+) from HNSCC patients were
plotted in A and B, respectively. Figure S2. Similar baseline expression
of CD16 on circulating monocytic MDSC in 08–013 responsers and
non-responders. Summary data of frequency of CD16+ cells and MFI of
CD16 in CD14+HLA-DRlo/- cells in responders (n = 10) and non-responders
(n = 19) of UPCI 08–013 trial pre-cetuximab treatment. Statistical significance
was determined by Mann Whitney test. (PPTX 553 kb)
Abbreviation
MDSC: Myeloid-derived suppressor cells; mAb: Monoclonal antibodies;
EGFR: Epidermal growth factor receptor; FcγR: Fc-gamma receptors; HNSCC: Head
and neck squamous cell carcinoma (HNSCC); MLR: Mixed leukocyte reaction;
ADCC: Antibody dependent cell-mediated cytotoxicity; APC: Antigen presenting
cells; ROS: Reactive oxygen species; ITAM: Immunoreceptor tyrosine-based activa-
tion motif; PBMC: Peripheral blood mononuclear cells; hIgG1: Human IgG1.
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